DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR LANOXIN PEDIATRIC
» See Plans and Pricing
All Clinical Trials for Lanoxin Pediatric
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00578617 | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | Duke Clinical Research Institute | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
| NCT00578617 | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | St. Jude Medical | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
| NCT00578617 | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | Mayo Clinic | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
| NCT00831506 | Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects | Completed | Medivation, Inc. | Phase 1 | 2009-02-01 | This study has been designed to confirm, in healthy subjects, the lack of a clinically important pharmacokinetic interaction between Dimebon, at the proposed maximum commercial dose of 20 mg TID (administered every 8 hours), and digoxin (Lanoxin®) 0.125 mg QD, a sensitive P-gp substrate recommended by FDA. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lanoxin Pediatric
Clinical Trial Locations for Lanoxin Pediatric
Trials by Country
Clinical Trial Progress for Lanoxin Pediatric
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Lanoxin Pediatric
Sponsor Name
